The Lancet Digital Health

Background Tobacco smoking during pregnancy increases the risk of preterm birth, small for gestational age (SGA), stillbirth, and longer-term adverse health outcomes. Globally, reducing smoking in pregnancy is a key public health priority, yet the organisation, accessibility, and effectiveness of cessation support varies substantially between countries and healthcare systems. Differences in policy implementation, resource allocation, and integration of cessation services into antenatal care influence uptake and success rates across diverse settings. In England, pregnant women are entitled to free smoking cessation support, however, service delivery varies across regions with mixed efficacy. While tobacco smoking is more prevalent in deprived communities, there is limited understanding of how, why, for whom, and under what circumstances these services are most effective, particularly in areas of social deprivation, such as the North East and Yorkshire. Objective To conduct a realist evaluation to understand how smoking cessation services support pregnant women in areas of social deprivation to stop smoking and reduce adverse perinatal outcomes. Methods This multi-site realist evaluation will be conducted across three NHS maternity services in West Yorkshire, England. The study comprises four iterative stages: (1) development of initial programme theories through realist-informed literature scoping and stakeholder consultation; (2) case study data collection including qualitative interviews with pregnant women (approximately 15-30) and staff (approximately 15-30); (3) analysis of routine anonymised maternity and neonatal electronic data collected over a one-year period; and (4) realist analysis to refine context-mechanism-outcome (CMO) configurations. Qualitative data will be analysed using realist logic supported by NVivo software. Quantitative data will be analysed using descriptive and inferential statistics to explore associations between smoking cessation engagement and perinatal outcomes. Ethics and dissemination Ethical approval was obtained through the UK Health Research Authority and a Research Ethics Committee prior to study commencement (IRAS 364173; REC reference number 26/SC/0020). Findings will inform recommendations to improve smoking cessation support for pregnant women in deprived areas. Results will be disseminated through peer-reviewed publications, conference presentations, and stakeholder engagement.

Background: Machine learning models trained on population health surveys offer scalable tools for cardiovascular screening, but recurring methodological weaknesses undermine their credibility and equity: data leakage from synthetic oversampling, qualitative rather than quantitative explainability evaluation, and the absence of demographic fairness auditing at the clinical operating threshold. Methods: We present EXHEART, a leakage-free stacked ensemble pipeline trained on BRFSS 2015 (n = 253,680) and validated on BRFSS 2020 (n = 319,795; temporal transport and retrain) and a clinical cardiovascular examination dataset (n = 68,730). The pipeline combines XGBoost, LightGBM, Random Forest, and a multi-layer perceptron as base learners with 5-fold out-of-fold logistic regression stacking and Platt scaling calibration. A quantitative SHAP-LIME consistency framework, based on Kendall-tau rank correlation and Jaccard overlap, accompanies a decision-curve analysis, a subgroup-stratified SHAP interaction analysis, and an intersectional fairness audit (Sex x Age x Income) with threshold-shifting mitigation and a frontier of the fairness-utility trade-off. The framework also adds cross-instrument fairness-disparity attribution, an empirical diagnostic that provides evidence on whether an observed subgroup disparity is more consistent with a measurement-induced or a substantive explanation by re-validating it on a dataset that measures the same clinical construct objectively. On heart disease, this diagnostic associates 89% of the sex TPR gap (95% CI [0.65, 0.99]) with the self-reported survey outcome rather than with a substantive risk difference. Results: On BRFSS 2015, EXHEART achieves AUC-ROC = 0.850, AUPRC = 0.371, Brier score = 0.071, and reduces ECE by 96% (0.256 to 0.011) via Platt scaling. Global SHAP-LIME rank agreement is moderate-to-strong (Kendall-tau = 0.580, Spearman-rho = 0.818) with a substantial top-3 divergence (Jaccard@3 = 0.200), where Stroke flips from SHAP rank 8 to LIME rank 1. The Sex TPR gap is 0.124 at the screening threshold; intersectional Sex x Age disparities reach 0.649 among adequately-powered cells, 5.2x the single-attribute gap. Temporal transport to BRFSS 2020 collapses sensitivity from 0.776 to 0.267, while retraining restores AUC = 0.840 and ECE = 0.012. On clinical examination data, the Sex TPR gap collapses to 0.014; the attribution test indicates this gap is instrument-dependent, consistent with a measurement or outcome-definition explanation rather than a substantive risk difference. Cross-domain SHAP analysis identifies four instrument-independent CVD risk factors and two major portability failures. Conclusions: EXHEART combines three practices that population-scale cardiovascular classifiers usually apply in isolation: leakage-free training with calibrated probabilities, a test of whether the model's explanations are stable, and a fairness audit that examines intersecting subgroups rather than single attributes. Bringing them together proved worthwhile. The intersectional audit revealed disparities that single-attribute auditing missed, and the cross-instrument comparison indicated that much of the sex gap reflects how the outcome is measured in survey data rather than a substantive difference in risk. The temporal transport findings indicate that deployed BRFSS models warrant periodic monitoring and retraining to maintain clinical utility. EXHEART is a retrospective methodological evaluation on public de-identified data; it is not validated for direct clinical decision-making, diagnosis, or treatment recommendation without prospective clinical validation.

Background: Cardiovascular-kidney-metabolic (CKM) syndrome is a leading driver of cardiovascular morbidity and mortality. Whole-body molecular imaging is well-positioned to phenotype such syndromes, yet no imaging biomarker quantifies cumulative CKM burden. Bone scintigraphy with 99mTc-labeled bisphosphonates is widely performed and expanding with transthyretin amyloidosis assessment, under which Perugini grade 0 (absent cardiac uptake) is considered clinically benign. Objective: We hypothesized that the soft tissue-to-bone ratio (STBR) on these scans captures CKM burden and is an independent prognostic biomarker. Methods: We retrospectively analyzed 8,769 consecutive patients without cardiac uptake on 99mTc-DPD whole-body planar scintigraphy. The primary endpoint was all-cause mortality. Secondary endpoints were major adverse cardiovascular events (MACE) and heart failure hospitalization. Cox models were adjusted for ten established cardiovascular risk factors. Imaging-phenotype association (IPA) analysis mapped STBR to 1,210 clinical traits. STBR distribution across CKM stages was assessed in four prespecified analyses, including a non-cancer subgroup. Results: During a median follow-up of 5.1 years (IQR 2.5-8.2), 2,418 deaths occurred. Patients with prespecified STBR >0.5 (n=772, 8.8%) had significantly higher mortality (adjHR 1.73, 95% CI 1.54-1.94, p<0.0001) with an adjHR of up to 3.42 at higher thresholds (95% CI 2.05-5.42, p<0.0001). Hazard increased monotonically with STBR. STBR >0.5 was independently associated with MACE (adjHR 1.51, 95% CI 1.11-2.05, p=0.008) and heart failure hospitalization (adjHR 1.31, 95% CI 1.02-1.67, p=0.03). The association was robust across all prespecified subgroups and sensitivity analyses, including continuous STBR and patients without renal insufficiency. IPA analysis identified significant associations with type 2 diabetes, chronic kidney disease, chronic ischaemic heart disease, heart failure, atrial fibrillation, liver disease, amyloidosis, and hypertension among binary traits, as well as with CRP, NT-proBNP, BUN, cholesterol (inverse), and hemoglobin (inverse) among continuous parameters. STBR increased monotonically across CKM stages in all sensitivity analyses (all p<0.0001). Conclusions: STBR derived from routine 99mTc-DPD bone scintigraphy in patients without cardiac uptake is an independent prognostic imaging biomarker associated with cumulative cardiovascular-kidney-metabolic burden. As an opportunistic measure from scans already acquired at scale, STBR could refine CKM risk stratification at no additional cost, radiation, or acquisition time.

Background: Safe reuse of multimodal hospital data for AI development is limited by the absence of reliable, context-aware deidentification across multimodal data and longitudinal patient data. Existing approaches are largely modality-specific and can indiscriminately remove clinically important information. Methods: We developed the Multimodal Anonymizer, a modular, locally deployable multi-agent framework integrating multimodal large language models, task-specific neural networks and rule-based transformations. We evaluated 16 orchestrator model configurations on a benchmark built from publicly available data and hospital data from our institution. The benchmark dataset included data from different origins: 250 MIMIC-IV patients with synthetically injected personally identifiable information (PII) supplemented with head CT, face images, handwriting, audio, German clinical-text datasets and local data. Primary outcomes were deidentification sensitivity and preservation of clinically important content; secondary analyses examined model characteristics, reproducibility, and performance against leading market and open-source solutions. Results: The best local configuration (the orchestrator being Qwen3-VL-235B-A22B-Thinking) achieved near-complete deidentification across all datasets, with per-patient sensitivity of 98.80% (95%-CI 97.20; 100), and per-PII sensitivity of 99.82% (95%-CI 99.76; 99.88). Critical clinical preservation was 99.60% (95%-CI 98.80; 100) per-patient, and clinical preservation was 99.61% (95%-CI 99.51; 99.71) per-file. All modalities achieved at least 98.30% sensitivity (lower bound 95%-CI). On our local data, the system achieved a deidentification sensitivity of 100% per-patient and per-PII; and a critical clinical preservation of 100% per-patient as well as a clinical preservation of 99.97% (95%-CI 99.91; 100) per-file. When comparing orchestrators, the leading local models were similar to proprietary models (GPT-5.2) in deidentification sensitivity while showing higher deidentification specificity. The Multimodal Anonymizer outperformed previous tools on most modalities. Conclusion: Near-complete, utility-preserving deidentification of multimodal clinical data is achievable with a unified, locally deployable multi-agent system, enabling safer large-scale reuse of hospital data for research and AI development.

Background: Molecular medicine has made genetic diagnostics crucial for rare diseases, but the majority of patients remains without diagnosis even after state-of-the-art assessment. Standardized systems for integrating clinical features, such as the Human Phenotype Ontology (HPO), offer assistance, but are often insufficiently detailed and fail to capture crucial clinical parameters such as age at onset, longitudinal changes in symptoms, detailed characteristics of a clinical symptom, or the absence of a feature. Results: We present Genosolver an integrated workflow that utilizes machine learning to address this bottleneck. Using Large Language Models (LLMs) and Large Reasoning Models (LRMs) on unstructured clinical notes and electronic health care data, we generate a workflow that unifies phenotype extraction, generates differential diagnosis, and prioritizes genetic variants from genome data. We evaluated the performance on 233 previously genetically solved cases, where Genosolver ranked the causative gene first in 72% of cases and in 94% of cases in the top 10 gene list, outperforming the existing benchmarking tool Exomiser by 9%. Semi-automated reanalysis of 1,875 unsolved rare disease cases yielded an additional diagnostic rate of 1.7%. Incorporating rich, unstandardized clinical narratives substantially enhanced model performance beyond HPO-only inputs and demonstrated competitive results using data security compliant local models. Conclusion: Integrating unstandardized clinical data with local LLMs and reasoning offers a scalable, data-secure workflow that increases molecular diagnoses in rare diseases.

Background Coeliac disease (CD) diagnosis on duodenal biopsies is limited by interobserver variability. We have previously demonstrated pathologist-level performance with our artificial intelligence (AI) model for the histopathological diagnosis of adult CD, but not in paediatric practice. As paediatric CD screening programmes expand internationally, accurate and scalable diagnostic tools are needed. We investigated whether an AI model trained exclusively on adult whole-slide images (WSIs) can generalise to paediatric CD diagnosis across independent centres. Methods A training and validation dataset of 9,958 WSIs from 8,421 adult patients (961 CD) from five centres was used to develop an ensemble of multiple-instance learning models using features from a foundation model. Testing was performed on 708 consecutive paediatric patients (86 CD) from two centres (Edinburgh and Southampton) not included in training. Model calibration was assessed, and probability outputs were grouped into clinically interpretable categories. Findings In adult cross-validation, the AI model achieved an area under the receiver operating characteristic curve (AUC) of 98.7%, sensitivity of 84.9%, specificity of 99.0%, and negative predictive value (NPV) of 98.1%. On testing (paediatric) datasets, performance remained high (AUC 98.8%, sensitivity 80.2%, specificity 98.4%, NPV 97.3%). Restricting analysis to predictions outside the intermediate-probability range (predicted CD probability <10% or [&ge;]65%; 85.3% of cases) improved sensitivity to 100% and specificity to 98.7%. No misclassifications were observed among high-confidence predictions (<2% or [&ge;]85%; 66.0% of cases). The expected calibration error was 0.03. Performance improved significantly when biopsies from both duodenal sites (bulb [D1] and descending [D2/3]) were considered. Interpretation Our AI model, trained on adult biopsies, generalises to paediatric CD diagnosis across centres and scanner platforms. Well-calibrated probability outputs provide clinically interpretable measures of diagnostic confidence and could support safe identification of CD-negative biopsies within defined thresholds. These findings demonstrate the feasibility of applying adult-derived AI models in paediatric populations and reinforce the importance of multi-site (D1 & D2) biopsy sampling.

Objective: Clinical phenotyping methods that rely on clinical and informatics expertise can be time-intensive and costly. We tested both manual and highly automated approaches using electronic health record (EHR) data to identify an FDA Sentinel Initiative health outcome of interest, acute pancreatitis. Materials and Methods: We trained and evaluated machine learning algorithms using EHR data with two approaches: a custom approach that included manually curated features and trained on outcomes data validated with medical record review, and a highly automated approach that greatly simplifies and automates feature engineering and relies on low-cost silver-standard outcomes for model training. Results: Custom algorithms using manually curated structured claims data discriminated cases from non-cases with a high degree of accuracy (cv-AUC 0.89 [95%CI 0.84-0.94]); the inclusion of natural language processing (NLP)-derived covariates from clinical notes increased performance slightly (cv-AUC 0.91[95%CI 0.86-0.97]). The automated algorithm trained on the outcome count of diagnosis codes performed less well (AUC 0.80 [95% CI 0.75-0.85]) but improved using maximum lipase value as an outcome (AUC 0.88 [95% CI 0.84-0.92]). At a positive predictive value of 90%, the custom algorithm had a sensitivity of 92%, the automated algorithm trained on diagnosis code count had a sensitivity of 45%, and the automated algorithm trained on maximum lipase value had a sensitivity of 84%. However, a prediction rule derived by clinicians during chart review was nearly as accurate (maximum lipase value [&ge;] 3 times upper limit of normal; AUC 0.86, PPV 85%, sensitivity 92%). Discussion: Machine learning algorithms with manually curated structured data and NLP features trained on validated outcomes data successfully identified validated events. Use of an outcome in the automated model based on specific phenotype knowledge (maximum lipase value) allowed for performance similar to the custom model and with considerably less resources.

Large language models (LLMs) such as ChatGPT are rapidly reshaping healthcare education and simulation-based training in non-technical skills (NTS), yet no bibliometric analysis has mapped this landscape. We searched seven open-access databases (OpenAlex, PubMed, Europe PMC, Crossref, Semantic Scholar, CORE, DOAJ) for English-language publications from January 2020 to March 2026. From 100,277 initial records, a sequential keyword funnel yielded 830 candidate papers, which were screened by 83 independent Claude Sonnet 4.6 AI agents applying pre-specified inclusion criteria (PRISMA-trAIce compliant; Cohen's kappa = 0.86 pre-reconciliation, 1.0 post-reconciliation). The final AI-verified corpus comprised 551 papers with a compound annual growth rate of 109%, contributions from 2,398 authors across 279 journals in 58 countries, and an h-index of 41. ChatGPT dominated the model landscape (46% of papers), with open-source models virtually absent. Virtual patient chatbots were the leading simulation modality (106 papers). Among NTS domains, communication (145 papers) and decision-making (135 papers) were most studied, whereas teamwork, leadership, situational awareness, and crisis resource management were markedly underrepresented. Only 6 urology-relevant papers were identified, none examining LLM integration within boot camp training formats. The field is growing at extraordinary pace but remains concentrated in a narrow range of NTS domains and a single proprietary model. Critical gaps persist in team-based skills training, open-source model evaluation, and specialty-specific simulation. AI-assisted bibliometric screening using multiple independent agents is feasible, reliable, and scalable, offering a replicable methodology for mapping fast-evolving research fields.

Background Healthcare-associated infections pose a major burden to neonatal health worldwide and remain difficult to track in low-resource hospitals because patient movement data and pathogen genomic data are rarely integrated into actionable transmission models. Existing approaches are often restricted to specific settings, highly structured electronic health records (EHRs), or analyses focused on either patient movements or pathogen characteristics alone. To address this gap, we developed PathoPath, an open-source integrative modelling platform, and evaluated its utility in a high burden paediatric hospital in Dhaka, Bangladesh. Methods PathoPath is an open-source R package that combines electronic health records with whole genome sequencing data to generate contact networks from direct and indirect contacts using minimal structured inputs. We retrospectively applied PathoPath to 373 cases of Klebsiella pneumoniae species complex (KpSC) infection identified in 2021 at the largest paediatric referral hospital in Dhaka, Bangladesh. Ward level patient movement trajectories were used to reconstruct contact networks, and genomic data from isolates from children <60 days were integrated to identify probable dissemination of bacterial clones and antimicrobial resistance plasmids. Findings PathoPath identified 750 direct contacts among 317 patients, forming 25 connected components, with the largest including 93 patients. KpSC infections were identified across 21 of 37 wards, with the neonatal intensive care unit accounting for 77.9% of all cases. Integration of genomic and network data distinguished sustained clustering of ST147 from multiple probable inter-clonal dissemination events involving IncFII plasmids carrying blaNDM-5 and/or blaOXA-181 within ST16. Four dominant sequence types accounted for 65.6% of sequenced isolates, and carbapenemase genes were detected in 95.8%. Interpretation PathoPath reconstructs hospital-wide contact networks and integrates them with pathogen genomics to map probable dissemination of pathogens and antimicrobial resistance using minimal structured clinical data. It could support more targeted infection prevention and control in hospitals where granular digital records are not available.

Background Emergency department (ED) triage is a high-stakes clinical decision process that determines patient prioritization and resource allocation under time pressure. Large language models (LLMs) have recently been proposed as decision-support tools for triage, yet most evaluations rely on simulated scenarios or curated datasets. Evidence from real-world clinical environments remains limited. The objective of this project was to systematically evaluate the performance, calibration, and reproducibility of multiple contemporary large language models for Emergency Severity Index (ESI) classification and sectoral allocation (ED vs. urgent care practice, UCP) using a comprehensive real-world triage dataset. Material and Methods Retrospective cross-sectional benchmarking study conducted at a tertiary academic emergency ED in Germany with an integrated central point of assessment (CPA). The study included all consecutive adult walk-in encounters (>18 years) presenting between October 2023 and February 2024 (N = 16,107). Data were collected from a structured clinical decision support system capturing presenting complaints, vital signs, and triage decisions recorded by specialized nursing staff. Structured clinical variables routinely collected at triage, including presenting complaint categories (CEDIS-PCL), vital signs according to the ABCDE framework, and additional structured or free-text clinical information. Results The primary outcome was the agreement between LLM-predicted and nurse-assigned ESI levels measured using quadratic-weighted Cohen's k. Secondary outcomes included sectoral assignment agreement, misclassification patterns (over- and under-triage), calibration metrics, and output reproducibility. Quadratic-weighted k values ranged from 0.18 to 0.75 across models. Only a structured stepwise prompting strategy achieved substantial agreement (k_qw = 0.747), approaching reported human inter-rater reliability. Most models demonstrated moderate or lower agreement and systematic overconfidence, with expected calibration errors (ECE) based on verbalized confidence ranging from 0.099 to 0.355. Sectoral assignment agreement (i.e. ED vs. urgent care practice, UCP) was uniformly low (k < 0.30). Reproducibility testing revealed substantial variability in 23% of cases, indicating non-deterministic output behavior for clinically relevant decisions. Conclusions Current large language models demonstrate heterogeneous and generally limited performance in real-world emergency triage tasks. Structured algorithm-guided prompting appears more influential than model architecture or size. Before clinical implementation, improvements in calibration, reliability, and workflow integration are required, alongside regulatory-compliant validation in prospective clinical settings.

Introduction: Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality, and low-dose aspirin (LDA) prophylaxis is the cornerstone of evidence-based prevention. Despite guideline recommendations, LDA adherence remains poor, with 10-25% of moderate-risk patients taking aspirin. Objective personalized risk stratification using biomarkers has been shown to motivate behavior change in other disease contexts. Survey data suggest that patients are more motivated to take aspirin if informed by an objective predictive test. Here, we report real-world LDA adherence among patients who received a high-risk result from a cell-free RNA (cfRNA) PE risk prediction test. Methods: This retrospective, observational survey study included asymptomatic patients of advanced maternal age (AMA; [&ge;] 35 years at delivery) with singleton pregnancies without USPSTF-defined preexisting high-risk conditions for PE who received the cfRNA PE risk prediction test. Patients who opted in to receive text message surveys were asked about LDA use following receipt of test results. High adherence was defined as reporting LDA use on at least 6 of 7 days per week at least 85% of the time surveyed. The primary analysis included patients with a high-risk test result and at least one LDA frequency survey response following receipt of test result. The observed proportion of adherent patients was compared to a baseline estimate of 25% using an exact binomial test. Results: Of 166 patients who received a cfRNA PE risk prediction test result, 48 (28.9%) received a high-risk result. Of these, 29 (60%) opted in and responded to at least one survey, constituting the primary analysis population. Twenty-seven of the 29 (93.1%; 95% CI: 78.0-98.1%) were classified as highly adherent, significantly higher than the 25% baseline adherence estimate for moderate-risk patients (p < 0.0001). Conclusion: Among surveyed patients who received a high-risk cfRNA PE test result, the proportion classified as highly adherent to LDA (93%) substantially exceeded published estimates of adherence in a similar patient population and met the clinically meaningful threshold of [&ge;] 80% associated with reduced risk of preterm preeclampsia. These findings indicate that objective and personalized biomarker risk testing may be a powerful driver of behavior change that current guidelines have failed to produce.

Between 2024 and 2025, Colombia universalized the Electronic Health Invoice with embedded Individual Health Services Delivery Records (RIPS -- Registro Background Between 2024 and 2025, Colombia universalized the Electronic Health Invoice with embedded RIPS records (FEV-RIPS) as the standard for financial and clinical data exchange. ADRES -- the entity responsible for administering the resources of Colombia's General Social Security Health System -- faced the challenge of processing information from multiple heterogeneous sources generated by more than 55,000 healthcare providers. Health systems in high-income countries converge clinical-financial data in consolidated platforms; Colombia started from a fragmented architecture with incompatible historical sources, no cross-database standardization, and no centralized analytical infrastructure until 2023. Objective We describe the design, technical challenges of integrating heterogeneous data, and operational performance of the analytical infrastructure built by ADRES to centralize large-scale processing of Colombian health system information, and derive transferable lessons for health system resource administrators in Latin America facing equivalent digitalization mandates. Methods Technical-descriptive report based on operational metrics from the ADRES Azure/Databricks environment during January-November 2025. We report indicators of data volume, processing speed, computational capacity, concurrent use by functional group, and governance structure. The architecture integrates VPN connectivity with MinSalud, automated processing of multiple formats (XML, relational tables, flat files), and a medallion data lake (Bronze/Silver/Gold). Data quality challenges include structural inconsistencies across sources, coding incompatibilities (municipalities, dates, diagnoses), format heterogeneities in unstructured data, and absent technical documentation. Results The platform manages 21 catalogs, 1,183 tables, and over 110,645 million stored records, with cumulative production exceeding 1 trillion processed records. It executes queries on 100 billion records in ten seconds using clusters of up to 32 TB RAM and 4,096 vCPU. During September-October 2025, monthly query peaks reached 78,028 across eleven functional groups. Integration required Python/PySpark parsers for variable-depth XML, equivalence tables for incompatible municipality codes, cleaning routines for extreme dates used as nulls (1900-01-01, 9999-12-31), and transformation logic bridging classic RIPS and FEV-RIPS. The platform supported econometric analyses, judicial mandate responses, and public interactive dashboards. Conversational AI integration (Genie, Copilot) extends analytical access to users without SQL knowledge. Conclusions ADRES built in one year an analytical infrastructure that provides, to our knowledge, the first published documentation of the systemic technical challenges of integrating heterogeneous data sources in a middle-income social security health system. Centralizing health system information at national scale is technically feasible under public institutional constraints -- but requires solving cross-source standardization problems the implementation literature does not document with quantitative precision. The derived lessons are transferable to health system resource administrators in Latin America facing equivalent challenges.

Background: In resource-limited settings, a critical bottleneck in cervical cancer prevention is the lack of practical strategies to triage high-risk human papillomavirus (HR-HPV)- positive women. Therefore, this study aimed to develop and internally validate a genotype-specific risk stratification model. Methods: A cross-sectional study enrolled 555 women in Cameroon. Data collection integrated cervical cytology and HPV genotyping using Abbott m2000rt and Sacace multiplex systems. An iterative modeling approach with bootstrap validation was used to develop the model and address model instability. HR-HPV genotypes were transformed into a hierarchical risk variable due to sparsity and integrated with significant predictors. The final model was translated into a scoring system, and the risk gradients and performances were evaluated at two thresholds. Data was analyzed using SPSS 27.0. Results: The mean age was 44.8 years, and the prevalence of HR-HPV was 26.5% (147/555). The final model, incorporating HPV categories, age, and tobacco, demonstrated moderate discriminative ability (AUC=0.702, 0.642-0.762) with a good calibration (Hosmer-Lemeshow {chi}{superscript 2}=4.05, p=0.399). The scoring system assigned women to risk groups based on their total scores which produced a clear monotonic risk gradient; the observed probability of high-grade lesions/cancer ranged from 15% (score 0) to >65% (score [&ge;]4). At a conservative threshold ([&ge;]4 points), 4.7% (26/555) of women were classified as high-risk, concentrating 46% (6/13) of cancers (positive predictive value[PPV]=58%) while a sensitive threshold ([&ge;]3 points) had 16.8% (93/555) high-risk, concentrating 77% (10/13) cancers (PPV=38%). Both thresholds maintained a high negative predictive value (>95%). Conclusion: This bootstrap-validated, risk-stratification tool is a proof-of-concept in resource limited settings that assigns HR-HPV-positive women to distinct management pathways using three variables. After refining through a longitudinal study and external validation, this scoring system can improve the efficiency of cervical cancer screening programs in low-resource settings.

Background. Blood-based biomarkers are increasingly proposed for identifying high-risk individuals before clinical disease and for making prevention-oriented trials more efficient. Prognostic enrichment can increase event rates, but trial efficiency also depends on whether the intervention effect is preserved in the enriched population. Methods. Using the UK Biobank Pharma Proteomics Project, we trained disease-specific proteomic risk scores (ProRS) from 2,916 plasma proteins with elastic-net Cox models. We compared ProRS, polygenic risk scores (PRS), and combined PRS--ProRS scores across ten incident diseases. We estimated cumulative incidence and theoretical two-arm time-to-event trial sample sizes across risk strata. To evaluate effect preservation, we examined six intervention-analogue exposure--outcome pairs spanning genetic (PCSK9/coronary artery disease, APOE/Alzheimer's disease, PPARG/type 2 diabetes, IL23R/Crohn's disease), behavioural (physical activity/all-cause mortality), and pharmacological (RAAS inhibitors versus calcium channel blockers/coronary artery disease) examples. Results. ProRS outperformed PRS for 9 of 10 diseases (median C-index 0.75 versus 0.61). ProRS and PRS were weakly correlated (median Pearson |r| = 0.04), and joint PRS--ProRS stratification identified groups with higher observed incidence than either score alone for several endpoints. In the top risk quartile, combined-score enrichment reduced theoretical required sample sizes by 32--74\% under a fixed 20\% relative hazard reduction. These gains were not always preserved when stratum-specific intervention-analogue effects were used. Effects were broadly preserved for APOE/Alzheimer's disease and physical activity/mortality. The PPARG/type 2 diabetes effect attenuated toward the null under all three score types, showing that event-rate enrichment does not guarantee effect preservation. For IL23R/Crohn's disease and the antihypertensive comparison, point estimates differed across score types -- preserved under polygenic but attenuated under proteomic enrichment -- but confidence intervals were wide and overlapping. Conclusions. Proteomic risk scores can identify high-event-rate populations for prevention-oriented trials, but event-rate enrichment alone is insufficient for trial design. Biomarker-guided enrichment should evaluate mechanism-specific effect preservation and may be preferable as a stratification or adaptive-design variable rather than as a restrictive eligibility criterion.

Medical discrimination may alter how patients relate to health information sources following adverse care encounters. We examined whether discrimination experience is associated with selective erosion of institutional health trust and with compensatory digital health engagement, using nationally representative data from the Health Information National Trends Survey (HINTS) 6 (2022; n=6,252) and HINTS 7 (2024; n=7,278). Survey-weighted modified Poisson regression estimated prevalence ratios (PRs) for binary high-trust outcomes, and survey-weighted ordinary least squares estimated coefficients for continuous outcomes; jackknife replicate weights (50 replicates) provided variance estimates. Discrimination was associated with substantially lower probability of high trust in the healthcare system (PR=0.39; 95% CI 0.30-0.52) and physicians (PR=0.85; 95% CI 0.77-0.94), with no significant association for trust in scientists, government, family, or religious organisations. The clinical-institutional pattern replicated in HINTS 6, which additionally showed reduced trust in scientists for race/ethnicity-based discrimination. Contrary to a disengagement hypothesis, discrimination-exposed adults showed higher probability of online health information seeking (PR=1.06), health app use (PR=1.11), and online provider messaging (PR=1.13); these associations persisted after adjustment for trust in physicians. Discrimination was independently associated with lower health self-efficacy (b=-0.271). Medical discrimination selectively erodes trust in clinical institutions while leaving broader epistemic trust largely intact. Despite this, discrimination-exposed patients engage more actively with digital health channels, consistent with compensatory reorientation toward non-clinical information sources. These findings describe engaged but institutionally alienated patients, with implications for restoring clinical trust and for equity-centred digital health design.

Background: Treatment decisions for carotid atherosclerotic disease rely primarily on luminal stenosis, although plaque vulnerability and symptomatic status better reflect short-term cerebrovascular risk. A scalable CTA tool for automated phenotyping of symptomatic carotid disease is lacking. Materials & Methods: In this multi-institutional retrospective study, 689 patients (mean age, 67.9 {+/-} 7.7 years; 366 men) from four hospitals were analyzed after screening 705 CTA examinations. 423 patients from one center were used for five-fold development and internal validation, and 266 patients from three centers for independent external validation. CarotidMamba, a deep learning framework combining dual foundation-model encoders with Mamba-based sequence modeling, was developed and benchmarked against clinical, radiomics, clinic-radiomics, CNN, and transformer comparators. Results: In the development cohort, CarotidMamba achieved an AUC of 0.839 (95% CI, 0.799-0.879) and accuracy of 0.825 (95% CI, 0.793-0.857), outperforming the strongest comparator by 0.066 and 0.050, respectively. External validation yielded AUCs of 0.897 (95% CI, 0.835-0.959) in YCH, 0.809 (95% CI, 0.720-0.898) in DCH, and 0.762 (95% CI, 0.649-0.875) in GH-NTC. CarotidMamba showed the lowest Brier score and expected calibration error across cohorts, with calibration slopes near 1.0. Conclusion: CarotidMamba provides an interpretable, clinically oriented, and externally validated CTA framework for phenotyping symptomatic carotid plaques, supporting vulnerability-aware imaging assessment beyond stenosis alone.

Objective. To introduce PsiBench, a clinically validated medication-safety benchmark for evaluating large language models (LLMs) against the standards used to certify hospital computerized provider order entry (CPOE) and electronic health record (EHR) systems, and a non-overlapping three-tier evaluation framework separating highest-stakes discrimination, the operational CDS regime, and category-correct alerting. Materials and Methods. PsiBench comprises 492 medication-safety scenarios across 11 safety categories, created by clinical pharmacology experts whose work underpins an annualized testing procedure used by more than 2,000 U.S. hospitals. The three-tier framework partitions the scenarios non-overlappingly: Discrimination (98 scenarios, 50 fatal vs 48 deception, near-balanced 51%/49%); Operational (394 scenarios, 261 serious unsafe plus 133 safe including 41 Excessive Alerts reclassified as operational negatives); and Attribution (311 alert-required scenarios). We evaluated 40 frontier LLMs from 10 providers over 3 runs per scenario at temperature 0.2 (or the provider default where temperature is not configurable), yielding 59,040 evaluations conducted April 21-23, 2026. Results. Headline binary performance on the full benchmark spans a wide range across the 40 models: F1 78.5%-92.3%, accuracy 65.4%-89.8%, sensitivity 81.4%-100.0%, specificity 6.1%-81.8%. Leading models by F1 (o4-mini 92.3%; o3 92.2%) pair high sensitivity with meaningful specificity; three models saturate sensitivity at 100% but fall below 25% specificity, indistinguishable from a naive always-alert classifier. The wide spread on a single headline metric motivates tier-specific analyses, developed in a separate clinical paper. Discussion and Conclusion. PsiBench and the three-tier framework operationalize a rigorous evaluation rubric for LLM medication safety, grounded in two decades of national hospital audit experience. The framework generalizes to any binary medication-safety classifier (rule-based, conventional ML, or LLM-driven), supporting tier-aware model selection and post-deployment surveillance.

Background: Two-thirds of Dutch cardiovascular risk management (CVRM) for patients at risk of cardiovascular disease is delivered in primary care practices. While individual risk scores are increasingly used during consultation, a population-level structure for risk-based patient outreach is not currently available. We therefore developed the PROSPERA programme, a multilevel intervention comprising population-level risk stratification and individual-level support tools. Aim: To assess anticipated and experienced barriers and facilitators among healthcare professionals (HCPs) to inform implementation in primary care. Methods: We conducted four focus groups and six interviews with nine primary care HCPs to explore anticipated and experienced barriers and facilitators. Inductive codes were thematically analysed and assigned to corresponding domains of the Theoretical Domains Framework (TDF) and the related Capability, Opportunity, Motivation model of Behaviour. Results: Barriers and facilitators were identified in 11 TDF domains. Population-level barriers included altered professional roles and limitations in technological infrastructure. Individual-level barriers were limited skills in interpreting risk calculations and difficulty integrating tools into clinical routine. Facilitators were related to beliefs on the importance of providing proactive care (population level), the use of U-Prevent for risk communication (individual level) and positive patient responses to the Lifestylecheck questionnaire (individual level). Conclusion: Addressing barriers and facilitators identified at both the population and individual levels can support implementation of the PROSPERA programme. Opportunities exist in education and training of HCPs in risk communication, as well as support in restructuring the physical and digital environment.

Background: Chronic diseases and symptom syndromes often develop after prolonged biological changes that may precede formal diagnosis. RNA-based metatranscriptomics captures active microbial and human gene expression and may provide a functional layer for disease risk evaluation. To address this translational gap, we developed and validated a Disease Risk Score (DRS) framework that integrates metatranscriptome-derived pathway activity scores from stool, saliva, and blood samples, and evaluated its potential clinical utility as an adjunct risk-evaluation tool. Methods: DRS uses disease-specific sets of pathway activity scores derived from stool and saliva microbial functions, stool and saliva microbial taxa, and blood human gene expression. For each disease, 'not optimal' pathway scores are aggregated into a normalized cumulative odds ratio, or cOR, using score-level odds ratios, statistical significance, and literature-supported biological relevance derived from a Development Cohort of 22,369 individuals. A cOR [&ge;] 5 is defined as high risk. Performance is evaluated in an independent Validation Cohort of 15,908 individuals using self-reported diseases as the reference. Disease support requires both significant cOR separation between self-reported and not-reported (Cohen's d [&ge;] 0.2) and risk ratio enrichment of self-reported disease among individuals classified as high risk (95% CI of Risk Ratio > 1). Results: Of 20 initially evaluated diseases, 15 meet the prespecified validation criteria on the independent validation cohort: ADHD, anxiety, chronic fatigue syndrome, depression, GERD, hypertension, inflammatory bowel disease, IBS-C, IBS-D, insomnia, MASLD, obesity, obstructive sleep apnea, Sjogren's syndrome, and type 2 diabetes. Five selected clinical scenarios illustrate how DRS can support clinician-mediated decision making, including IBS subtype reclassification, improved diagnostic acceptance in IBS-D, personalized lifestyle counseling in MASLD and early type 2 diabetes, and diagnostic uncertainty in atypical GERD. Conclusions: DRS is a metatranscriptomics-based risk-stratification framework that aggregates active microbial and human pathway signals into interpretable disease-specific risk estimates across a wide range of disease conditions. Validation against self-reported disease labels in an independent cohort shows significant risk enrichment for each of 15 diseases. DRS is intended as an adjunct to clinical evaluation: a decision support tool in situations where routine care encounters uncertainty, delay, or low patient engagement. Future prospective studies using clinically adjudicated endpoints are needed to assess calibration and clinical outcomes.

Background: Machine learning models for stroke mortality prediction typically treat each time horizon independently and use flat tabular features that ignore the relational structure of electronic health records (EHRs). In this pilot study, we leveraged graph-based machine learning models to predict post stroke all-cause-mortality across three different time horizons. Methods: We developed Stroke Temporal Heterogeneous Graph (StrokeTHG), a heterogeneous graph neural network model for simultaneous multi-horizon stroke mortality prediction (30-day, 90-day, 1-year) using EHR data from Penn State Health System. The model encodes various relations among EHR entities (e.g., patient, diagnosis, comorbidity) and temporal encoding of admission time to better predict stroke mortality. We compared our proposed approach against various baseline methods, including Logistic Regression, Random Forest, and XGBoost. We also performed ablation and subgroup analyses, evaluated the quality of learned graph embeddings, and assessed the importance of different edge types in the graph. Results: We included 4,144 stroke patients (mean age 69.2 years; 54.3% men), of whom 3,332 (80.4%) survived their stroke after one year. 30-day, 90-day, and 1-year mortality rates were 9.7%, 13.7%, and 19.6%, respectively. Our proposed approach, StrokeTHG, achieved AUROC of 0.872, 0.878, and 0.837 across horizons, outperforming all tabular baselines. At [&ge;] , 75% specificity, the model identified 5-10 percentage points more mortality cases than the best baseline at each horizon. Subgroup analysis demonstrated consistent performance across sex subgroups and the largest discriminative gains in the Age 65-80 stratum. Edge-type ablation identified phenotype-patient and admission-patient edges in the constructed EHR graph as the most influential relational edges for mortality prediction. StrokeTHG embeddings outperformed all graph and matrix factorization baselines under an identical downstream classifier, confirming that performance gains stem from representation quality rather than classifier capacity. Conclusions: StrokeTHG demonstrates that heterogeneous graph representations of EHR data provide a consistent improvement over flat tabular models for multi-horizon stroke mortality prediction, with particular advantage at clinically actionable sensitivity thresholds and novel multi-horizon monotonic prediction capability. This methodological framework may be adaptable to other EHR-based clinical research studies seeking to leverage heterogeneous relational structures for predictive modeling.